Oncolytics Biotech Reports 3-4x Improvement in Colorectal Cancer Response Durability, Pursues Accelerated FDA Approval
ONCY has more than doubled off its 52-week low of $0.326.
Summary
Oncolytics Biotech announced highly positive durability and response rate data from its REO 022 study in metastatic colorectal cancer, leading to discussions with the FDA for a potential accelerated approval pathway.
Key Events · Product Development and Regulatory · ONCY
-
Significant Improvement in Response Durability
Pelareorep-based therapy achieved a 19.5-month median duration of response in 2L KRAS-mutant MSS mCRC, a 3-4x improvement over historical benchmarks of 4-6 months.
-
Tripled Objective Response Rate
The study also showed a 33% objective response rate, tripling the 6-11% typically seen with standard of care in this patient population.
-
Pursuing Accelerated FDA Approval
The company is actively engaging with the FDA to discuss a potential accelerated approval pathway for pelareorep in 2L RAS-mutant MSS mCRC, leveraging these strong durability and time-to-event endpoints.
-
Critical for Financially Challenged Company
This positive clinical data is crucial for Oncolytics Biotech, which previously disclosed a 'going concern' warning and relies on dilutive financing, potentially improving its ability to secure future capital.
Analysis · ONCY · Life Sciences
This filing is highly significant for Oncolytics Biotech, a company facing a "going concern" warning and relying on dilutive financing. The reported 3-4x improvement in median duration of response (19.5 months vs. 4-6 months historical) and tripling of objective response rate (33% vs. 6-11%) in a difficult-to-treat metastatic colorectal cancer population (RAS-mutant MSS mCRC) are compelling clinical outcomes. The active engagement with the FDA to discuss a potential accelerated approval pathway based on these results could dramatically shorten the time to market and provide a crucial lifeline, validating the company's drug pelareorep and potentially improving its future financing prospects.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 39.5% of the 352 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101M. The 52-week trading range was $0.33 to $1.51. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.